At present, it is reported that AT7867 is an effective orally active AKT inhibitor, and it has been confirmed that it has the ability to inhibit tumor cell proliferation and induce tumor cell apoptosis, especially in CRC [14]. The gene discussed is AKT1; the disease is colorectal carcinoma.